GlassScriptPhysician profile
Laura L Luke
NPI 1073612032
$422.85
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $370 · 2022: $53.17.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $229.76 | 2021 | |
| Indivior INC. | $46.01 | 2021 | |
| Sun Pharmaceutical Industries INC. | $29.02 | 2021 | |
| Gilead Sciences, INC. | $20.96 | 2022 | |
| Glaxosmithkline, LLC. | $19.99 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.65 | 2021 | |
| Lilly USA, LLC | $16.89 | 2021 | |
| Janssen Biotech, INC. | $15.56 | 2021 | |
| Genzyme Corporation | $13.79 | 2021 | |
| Abbott Laboratories | $12.22 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Luke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.